The Awareness of and Adherence to the Pregnancy Prevention Program for Oral Retinoids and Valproate: A Questionnaire Survey among Pharmacy Technicians Denmark

Background The use of oral retinoids and valproate during pregnancy can cause birth defects. In 2018, the EMA revised Pregnancy Prevention Programs (PPPs) for these medications. Pharmacy technicians in Denmark dispense prescription medications and must counsel customers. Aims This study aimed to examine knowledge of the teratogenicity of oral retinoids and valproate and use of the relevant PPPs among pharmacy technicians in Denmark. Methods A cross-sectional survey was conducted in spring 2025 using questionnaires developed for and tested in an international project. Data was collected via relevant Facebook groups and email invitations. Descriptive statistics were used for analyses. Results For oral retinoids, 80 respondents were analyzed; 95% were women, 86% were pharmacy technicians, the mean age was 37.2 years. Most dispensed oral retinoids several times per month. Two respondents did not know retinoids were teratogenic. The most used PPP measure was the outer packaging warning (54%). Informing women about teratogenic effects was the most common practice. For valproate, 41 respondents were analyzed. Their characteristics were similar to those of respondents in the oral retinoid survey. Most dispensed valproate once per month. One-third did not know valproate was teratogenic. The outer packaging warning was used by 19%. The most common practice was referring to the prescribing physician if pregnancy was suspected. Conclusion Danish pharmacy technicians knowledge about teratogenic drugs and the PPP was poorer than that of pharmacists, especially regarding valproate, and requires attention in educational programs. The feasibility of PPP measures for both oral retinoids and valproate should be optimized.